Payment overview · 2025
General Payments
$655.75
38 reported records · 16 companies
Healthcare provider profile · identity verified
Stephen L Cullen, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WASHINGTON, IN · NPI 1760456305
Verified facts
What the public records show
CMS Open Payments records show Stephen L Cullen, D.O. received $655.75 in general payments during 2025 across 38 reported records.
ABBVIE INC. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $204.73 | 31.2% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.49 | 10.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.52 | 9.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.04 | 8.2% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.16 | 5.4% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $34.00 | 5.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.58 | 5.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.85 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.28 | 3.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.79 | 3.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.42 | 3.1% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $20.03 | 3.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17.94 | 2.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.88 | 2.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.31 | 2.2% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $11.73 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $655.75 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $106.40 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $106.40 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.14 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.49 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $61.52 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.94 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.94 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.58 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $11.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
177 | 177 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 542 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 472 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 452 | 107 |
| Lisinopril | Lisinopril | 428 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 73 |
| Omeprazole | Omeprazole | 212 | 47 |
| Furosemide | Furosemide | 211 | 61 |
| Losartan Potassium | Losartan Potassium | 197 | 47 |
| Metformin Hcl | Metformin Hcl | 195 | 53 |
| Gabapentin | Gabapentin | 189 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 42 |
| Potassium Chloride | Potassium Chloride | 179 | 47 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 177 | 177 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 159 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 36 |
| Allopurinol | Allopurinol | 136 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 36 |
| Eliquis | Apixaban | 128 | 21 |
| Metformin Hcl Er | Metformin Hcl | 124 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 20 |
| Montelukast Sodium | Montelukast Sodium | 93 | 22 |
| Pregabalin | Pregabalin | 93 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 21 |
| Glimepiride | Glimepiride | 85 | 17 |
| Ozempic | Semaglutide | 84 | 16 |
| Tramadol Hcl | Tramadol Hcl | 81 | 18 |
| Alprazolam | Alprazolam | 79 | 19 |
| Meloxicam | Meloxicam | 78 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 20 |
| Famotidine | Famotidine | 66 | 14 |
| Simvastatin | Simvastatin | 65 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 17 |
| Temazepam | Temazepam | 56 | suppressed |
| Carvedilol | Carvedilol | 55 | 11 |
| Ezetimibe | Ezetimibe | 55 | suppressed |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Cephalexin | Cephalexin | 52 | 39 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | 13 |
| Nystatin | Nystatin | 49 | 18 |
| Ibuprofen | Ibuprofen | 47 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | suppressed |
| Lovastatin | Lovastatin | 46 | 12 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 14 |
| Risperidone | Risperidone | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 18 |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 21 |
| Naproxen | Naproxen | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 12 |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $655.75 · 38 records | ABBVIE INC. | Auvelity, Azstarys, CAPLYTA, Dexcom G6 Transmitter, EVENITY, JARDIANCE, Jornay PM, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, SX-ONE MICROKNIFE, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, ZEPBOUND, ZURZUVAE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error